leap:up

leap:up GmbH (formerly biosaxony Management GmbH) supports founders, startups, and SMEs in the life sciences on their path to innovation, market entry, commercialization, and growth. We connect medical technology, biotechnology, and the healthcare sector, creating a unique alliance of life science stakeholders in the heart of Europe. Based at BioCity Campus Leipzig, a hub exclusively dedicated to life science companies and research institutions, we are embedded in a fully integrated cluster in Central Germany. With around 300 biotech, medtech, and healthcare companies, 80 hospitals, and more than 30 research institutions, Saxony provides exceptional collaboration opportunities.
leap:up im Überblick:
| Field of Activity | Acceleration, regulatory support, training, events, co-working labs, plus international services incl. funding & investor relations. |
| Ownership Structure and Financing | Wholly-owned subsidiary of biosaxony e.V., Saxony’s life sciences association representing biotech, medtech, healthcare & related sectors. |
| Partners | Partners include the City of Leipzig’s Economic Development Department and BIO CITY Leipzig as a leading innovation hub. |
| Technology | Our focus areas include diagnostics, cell and gene therapy, radiopharmacy, smart medical devices, robotics and AI, digital health, and phage therapy. |
| Products/ Services |
|
| Unique Selling Point | One-stop shop: management & consulting for networks, founders, startups, SMEs, and infrastructure – all from a single source. |
Kontakt:
| Adresse | leap:up GmbH Deutscher Platz 5c 04103 Leipzig, Germany |
| info@leap-up.com | |
| Social Media | leap:up GmbH | LinkedIn |
| Web-Adresse | leap:up – The Life Science Enabler |
| Date of Incorporation | 2009 |
| Number of Employees | 27 |
ARTIKEL ZU DIESEN SCHLAGWORTEN
- SK Hynix feiert Rekord-Börsengang in den USA
- GCC-/MENA-Märkte für Europas Life Sciences
- Reichweite der Botschaft messen
- Geschäftsbericht neu denken
- Case Study: OptoGenTech – Hören mit Licht
- Out Now: GoingPublic 2/2026
- „Gut gerüstet für weiteres Wachstum“
- Unterschätzter Softwarehebel?
- Case Study: BIONCaRT – Stammzellen für die Regeneration geschädigter Gelenke
- Kommt das dicke Ende noch?
- Wirkung durch Sichtbarkeit
- Buzzword oder Businessmodell? Warum KI in der Equity Story zur Glaubwürdigkeitsfrage wird
- IPO-Markt USA
- Out now! Special „Mitarbeiterbeteiligung 2026“
- Partnerschaften als Motor für Transformation und Wachstum
- mbiomics: „Die eigentliche Differenzierung erfolgt über das Manufacturing“
- Palfinger AG
- Bessere Lage dank Forschungszulage
- DBT 2026: Morgens um 8 in Deutschland
- Viromed Medical AG